Selank is a synthetic heptapeptide engineered from the natural tuftsin sequence to enhance metabolic stability and regulatory potential in research settings. Its structure, Thr–Lys–Pro–Arg–Pro–Gly–Pro, reflects a stabilized extension of the endogenous IgG-derived regulatory motif.
In experimental models, Selank has been investigated for its ability to modulate stress-related neurochemical pathways. One of its most frequently discussed mechanisms is the inhibition of enkephalin-degrading enzymes, which may prolong the activity of endogenous opioid peptides in vitro.
Selank is also studied for its influence on neurotrophic factors, particularly BDNF expression in rodent learning and memory models. These findings support its use in research exploring neuroplasticity, cognitive function, and adaptive behavioral responses.
A growing body of work associates Selank with neuroimmune regulation, including modulation of cytokine, chemokine, and receptor gene expression. These immune-linked effects highlight Selank’s potential relevance in examining the intersection of stress biology and inflammatory signaling.
Behavioral studies commonly evaluate Selank in stress-resilience paradigms, anxiety-related assays, and models involving affective regulation. Such experiments emphasize its role as a neuromodulatory peptide rather than a direct receptor agonist.
Additional research explores Selank fragments and structure–activity relationships, demonstrating that minor sequence changes can alter experimental outcomes. This underscores Selank’s utility for studying short-peptide regulatory mechanisms and peptide–protein interaction dynamics.
While Selank has been investigated clinically in limited regions, it is not an FDA-approved therapeutic and is positioned strictly as an experimental compound. Its most appropriate use is within controlled laboratory environments focused on neural, immune, or peptide-regulatory pathways. For laboratory research use only, not for human or veterinary use.
